CYP19A1 and breast carcinoma: In the comparison of an endocrine therapy with an aromatase inhibitor to tamoxifen in postmenopausal women, the aromatase inhibitor was associated with about one-third fewer recurrences during the treatment period and with approximately 15% fewer deaths from breast cancer during the first decade [4].